Full Archive

Phase I Clinical Trial Underway for CAR T-cell Therapy

A Phase I clinical trial for an immunotherapy treatment for malignant pleural mesothelioma and non-small cell lung cancer (NSCLC) is currently underway at the University of Pennsylvania in Philadelphia. Immunotherapy treatments support the body’s immune system response to diseases. It is often looked to as a positive alternative for treating[…]

Read More »

Pembrolizumab Update: Aduro Biotech Collaborates with Merck

A biopharmaceutical company named Aduro Biotech recently announced its collaboration with Merck to further evaluate the findings for the Phase II trial of KEYTRUDA ® (pembrolizumab) and to combine their own immunotherapy treatment, CRS-207. Information regarding KEYTRUDA ® treatment began to circulate late last year when data presented at the[…]

Read More »

Bevacizumab (Avastin): Part of a New Treatment Regimen for Mesothelioma Patients

The results of a 2016 Phase III trial of the monoclonal antibody bevacizumab (Avastin) have established another option for treatment for those suffering from malignant pleural mesothelioma. Angiogenesis, which is the formation of new blood vessels, plays a key role in mesothelioma because it allows the tumors and cancer to[…]

Read More »

Success in Lung Cancer Treatment Gives Hope to Mesothelioma Patients

The latest success concerning a treatment for non- small cell lung cancer (NSCLC) has scientists and researchers hopeful that the same treatment can be applied to mesothelioma victims. The Phase III trial for Alecensa (alectinib), while currently not recruiting participants, is on-going and results thus far have shown to be[…]

Read More »

Treatment Used In Multiple Sclerosis May Be Used In Mesothelioma

Although still in the preliminary stages, scientists and researchers are excited to announce recent research involving a treatment that is used for certain types of multiple sclerosis (MS) and its effects on combating mesothelioma. This therapeutic agent is called Immune System Modulator FTY720 (fingolimod) and is interestingly derived from a[…]

Read More »

Nintedanib and Pembrolizumab – Hope for Mesothelioma Patients

The latest findings in cancer treatments for the often fatal mesothelioma have scientists and researchers hopeful that they are one step closer in finding a consistent, effective treatment for the asbestos-caused cancer. The LUME-Meso Phase II trial for patients with malignant pleural mesothelioma focused on the administration of the triple angiokinase[…]

Read More »

National Asbestos Awareness Week: April 1 – April 7, 2017

On March 29, 2017 the U.S. Senate passed S. Res.98; a resolution designating the first week of April as “National Asbestos Awareness Week” in an attempt to warn and educate the public about asbestos exposure and its deadly health effects. Despite it being a known carcinogen and its ban in[…]

Read More »

Your Asbestosis Could Lead to Lung Cancer or Mesothelioma

Asbestosis, while not a cancerous condition, is serious and potentially life-threatening chronic disease that is caused by breathing in asbestos fibers. A person who has been diagnosed with asbestosis has a much higher chance of developing lung cancer or pleural mesothelioma, a fatal cancer affecting the lining of the lungs.[…]

Read More »

Call Your State Senators to Oppose the Furthering Asbestos Claims Transparency Act

A new bill was approved by the U.S. House Judiciary Committee that could damage the asbestos claims process and prevent victims of asbestos-related diseases from ever seeing any sort of monetary compensation before they pass. The legislation is “H.R. 906” and is referred to as the “Furthering Asbestos Claims Transparency[…]

Read More »